Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F136 - Pharmacy Compounding and the Dermatologist

Monday, February 19; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe the basic tenets of Pharmacy Compounding as it applies to dermatology, including when extemporaneous compounding is a useful supplement to currently available marketed drugs in the U.S.
  • Recognize the need for a safe drug supply in the context of Pharmacy Compounding
  • Summarize the role of FDA in regulating Pharmacy Compounding and discuss the history of untoward events related to Pharmacy Compounding

Description

The attendee will learn in brief a history of pharmacy compounding, modern pharmacy compounding, and the events that led up to the current regulatory environment for pharmacy compounding. Focus will be provided on dermatology compounding, what aims are sought to be achieved, what special populations benefit most from compounding.

Disclosures

  • Alam, Murad, MD: Allergan, Inc – C(Fees); Bonti – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Pulse Biosciences – C(Fees); Revance Therapeutics, Inc. – I(Grants/Research Funding);
  • Dohm, Julie, PhD, JD: no financial relationships exist with commercial interests.
  • Luke, Markham C., MD, PhD: no financial relationships exist with commercial interests.
  • Pattanshetti, Natasha: no financial relationships exist with commercial interests.
  • Siegfried, Elaine C., MD: Allergan, Inc – I(Fees); Amgen – I(OB); Dermavant Sciences – C(Fees); Eli Lilly and Company – I(Fees); GlaxoSmithKline – Data Safety Monitoring Board(Fees); Janssen Pharmaceuticals, Inc – I(Fees); Mayne Pharma Group – I(Fees); Medimetriks Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees); Novan – C(Fees); Pfizer Inc. – A(Fees); Pierre Fabre Dermo-Cosmétique US – I(Fees); Regeneron – I(Fees); Valeant Pharmaceuticals North America LLC – C(Fees); Verrica Pharmaceuticals Inc – A(Fees);
  • Wilkerson, Michael G., MD: no financial relationships exist with commercial interests.
Schedule
Monday, February 19
1:00 PM
Dr. Luke / Introduction
1:05 PM
Dr. Dohm / What is Pharmacy Compounding?
1:15 PM
Dr. Dohm / FDA's Role In Pharmacy Compounding
1:45 PM
Dr. Luke, Dr. Wilkerson, Dr. Siegfried, and Dr. Alam / Panel: Pharmacy Compounding and the Dermatologist
2:15 PM
Pattanshetti and Dr. Alam / AAD and Pharmacy Compounding
2:40 PM
All faculty / Consensus/Future Direction
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 5B
  • CME Credits
    2.00
  • Type
    New
Directors/Co-Directors
  • Markham C. Luke, MD, PhD, FAAD - Handout
Speakers
  • Elaine C. Siegfried, MD, FAAD - Handout
  • Julie Dohm, PhD, JD
  • Michael G. Wilkerson, MD, FAAD
  • Murad Alam, MD, FAAD
  • Natasha Pattanshetti